NYSEAMERICAN:PFNX Pfenex (PFNX) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free PFNX Stock Alerts $12.75 0.00 (0.00%) (As of 10/1/2020) Add Compare Share Share Today's Range$12.75▼$12.7550-Day Range N/A52-Week Range$5.26▼$14.00VolumeN/AAverage Volume503,865 shsMarket Capitalization$437.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pfenex alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Pfenex Stock (NYSEAMERICAN:PFNX)Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Read More PFNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PFNX Stock News HeadlinesJanuary 31, 2024 | morningstar.comNKY Medical Holdings Ltd Class A 300109September 25, 2022 | seekingalpha.comLigand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking AlphaApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.August 15, 2022 | businesswire.comForte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business WireAugust 9, 2022 | businesswire.comLigand Reports Second Quarter 2022 Financial Results - Business WireAugust 8, 2022 | stockhouse.com2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - StockhouseMay 17, 2022 | finance.yahoo.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo FinanceMay 5, 2022 | streetinsider.comLigand Reports First Quarter 2022 Financial Results - StreetInsider.comApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.May 4, 2022 | marketscreener.comLigand Reports First Quarter 2022 Financial Results - Marketscreener.comMarch 29, 2022 | seekingalpha.comLigand Pharmaceuticals: Moving Parts Keep Moving - Seeking AlphaMarch 24, 2022 | prnewswire.comGlobal Pharma, Biotech and Diagnostics Joint Venture Partnering Deal Terms and Agreements Analysis Report 2021 with Example Case Studies of Agila Specialties/Pfenex and Dance Biopharm/Harmony Asset - PR NewswireFebruary 17, 2022 | businesswire.comLigand Reports Fourth Quarter and Full Year 2021 Financial Results - Business WireFebruary 15, 2022 | businesswire.comPipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors - Business WireJanuary 14, 2022 | marketscreener.comLIGAND PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.comJanuary 5, 2022 | businesswire.comDr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer - Business WireNovember 10, 2021 | nasdaq.comSolid Nutrition Unit to Aid Archer Daniels (ADM) Amid Cost Woes - NasdaqNovember 10, 2021 | nasdaq.comDare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - NasdaqNovember 10, 2021 | nasdaq.comfuboTV Falls 7% Despite Solid Q3 Results - NasdaqNovember 9, 2021 | marketscreener.comLIGAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.comNovember 9, 2021 | businesswire.comLigand Reports Third Quarter 2021 Financial Results - Business WireSeptember 23, 2021 | benzinga.comGlobal Joint Venture Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - B - BenzingaSeptember 7, 2021 | yahoo.comOphthalmology Biosimilars Market Report 2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast - Yahoo FinanceJuly 30, 2021 | fool.comLigand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript - Motley FoolJuly 29, 2021 | businesswire.comLigand Reports Second Quarter 2021 Financial Results - Business WireSee More Headlines Receive PFNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:PFNX Previous SymbolNYSEMKT:PFNX CUSIPN/A CIKN/A Webwww.pfenex.com Phone+1-858-3524400FaxN/AEmployees71Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,297,000Free FloatN/AMarket Cap$437.29 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Evert B. Schimmelpennink (Age 47)CEO, Pres, Sec. & Director Ms. Patricia Lady C.M.A. (Age 61)CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer Mr. Patrick K. Lucy (Age 51)Chief Bus. Officer Dr. Hubert C. Chen (Age 50)Advisor Ms. Susan A. Knudson (Age 55)Chief Financial Officer Key CompetitorsCybinOTCMKTS:CYBNNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEBiopharmxNYSEAMERICAN:BPMXAveanna HealthcareNASDAQ:AVAHView All Competitors PFNX Stock Analysis - Frequently Asked Questions How were Pfenex's earnings last quarter? Pfenex Inc. (NYSEAMERICAN:PFNX) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to analyst estimates of $3.75 million. Read the conference call transcript. What other stocks do shareholders of Pfenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Verastem (VSTM), SCYNEXIS (SCYX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Novavax (NVAX) and Ocular Therapeutix (OCUL). How do I buy shares of Pfenex? Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:PFNX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfenex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
